BRIEF-Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102
March 23, 2017 at 08:17 AM EDT
* Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102 for treatment of Arginase I deficiency at 2017 ACMG annual clinical genetics meeting